Close Menu

NEW YORK – The Advanced Diagnostic Laboratory Test (ADLT) status provided for by the Protecting Access to Medicare Act (PAMA) has seen little uptake by clinical labs thus far, but recent developments suggest that could be changing.

In May, three tests received ADLT approval, bringing the total number of ADLTs from two to five, and at the recent Centers for Medicare & Medicaid Services Clinical Lab Fee Schedule, several firms discussed pursuing the designation, including Myriad Genetics, which is exploring ADLT status for its MyPath Melanoma assay.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.